Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases (Reuters, 10 February 2012)
Norway-based Algeta ASA has announced completion of a phase III trial evaluating Alpharadin (radium-223 chloride) in patients with castration-resistant prostate cancer and bone metastases.
Full article